https://trial.medpath.com/news/darolutamide-shows-promising-results-in-treating-metastatic-hormone-sensitive-prostate-cancer 2024-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designations-to-two-novel-aml-therapies 2024-02-22T16:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-car-t-cell-therapy-offers-new-hope-for-autoimmune-disease-patients 2024-02-22T11:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/indian-pharmaceutical-giants-race-to-develop-generic-versions-of-wegovy-as-global-weight-loss-market-approaches-100-billion 2024-02-22T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-pivots-beyond-covid-19-with-rsv-vaccine-launch-reports-better-than-expected-q4-profits 2024-02-22T03:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-acquires-boston-pharmaceuticals-efimosfermin-for-liver-disease-in-2-billion-deal 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-indigenous-car-t-cell-therapy-revolutionizes-cancer-treatment-at-one-tenth-global-cost 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-a-mixed-response-to-a-petition-seeking-greater-clinical-trial-transparency 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-an-artificial-intelligence-based-clinical-trial-matching-system-for-hepatocellular-carcinoma 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-announces-amendment-and-extension-of-exclusive-supply-and-distribution-agreement-with-baxter-healthcare-corporation-financial-post 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-hold-on-studies-of-zelnecirnon-rpt193-in-atopic 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-shares-rise-after-fda-fast-track-status-for 2024-02-20T14:54:06+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-glofitamab-expands-treatment-horizons-for-multiple-b-cell-lymphomas 2024-02-20T10:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/atropos-health-and-seqster-partner-to-revolutionize-healthcare-data-analytics-with-ai-powered-patient-registries 2024-02-20T03:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-gets-new-tagrisso-ok-as-drug-succeeds-in 2024-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cyclarity-therapeutics-advances-in-developing-a-plaque-busting-molecule-for-atherosclerosis 2024-02-19T11:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-clinical-data-management-systems-revolutionize-biotech-trials 2024-02-19T05:22:12+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/double-blind-trial-shows-comparable-efficacy-in-treatment-and-control-groups-for-gastric-symptoms 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/houtou-jianweiling-tablet-shows-promise-in-treating-chronic-non-atrophic-gastritis 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/largest-covid-vaccine-study-yet-finds-links-to-health-conditions-bloomberg 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-osimertinib-plus-chemo-for-egfr-mutated-nsclc 2024-02-16T21:54:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-tigilanol-tiglate-for-soft-tissue-sarcoma-treatment 2024-02-16T18:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/nexicart-1-safety-and-efficacy-of-nxc-201-in-al-amyloidosis 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/als-drug-from-denali-sanofi-falls-short-in-mid-stage-study 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adi-peg20-quadruples-three-year-survival-in-phase-3-mesothelioma-trial 2024-02-15T16:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/scope-summit-2024-patient-centricity-and-ai-drive-clinical-trial-innovation 2024-02-15T07:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-announces-major-milestone-by-reaching-its-interim-enrollment-target-of-90-patients-financial-post 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcomes-before-and-after-prucalopride-treatment-an 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemohormonal-therapy-shows-promise-for-high-risk-prostate-cancer 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-set-to-transform-drug-development-landscape-in-2024-from-clinical-trials-to-supply-chain-optimization 2024-02-14T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/grifols-biotest-achieves-phase-3-success-for-fibrinogen-concentrate-in-acquired-deficiency-treatment 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/publication-in-diabetologia-highlights-ai-s-potential-for-type-1 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/st-jude-scientists-develop-novel-bispecific-car-t-design-to-combat-acute-myeloid-leukemia-relapse 2024-02-13T14:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-embraces-ai-integration-in-clinical-trials-while-emphasizing-safety-and-guidance 2024-02-13T13:43:38+00:00 weekly 0.7 https://trial.medpath.com/news/pasithea-therapeutics-announces-enrollment-opening-for-pas-004-phase-1-clinical-trial 2024-02-13T07:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/hmnc-brain-health-advances-precision-psychiatry-with-novel-oral-ketamine-study-for-treatment-resistant-depression 2024-02-13T03:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-immunotherapy-treatment-options 2024-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-gsk-s-bepirovirsen-for-chronic-hepatitis-b-treatment 2024-02-12T16:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-at-scope-summit-2024 2024-02-12T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-mrna-s-q4-results-rapt-down-on-study-results-other 2024-02-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-outcomes-of-advanced-renal-cell-carcinoma-treatment-with-immune-oncology-combinations 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4dmt-presents-interim-data-from-4d-310-inglaxa-phase-1-2-clinical-trials-for-fabry-disease-cardiomyopathy-at-worldsymposiumtm-2024 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-survival-outcomes-in-bladder-cancer-treatment-study 2024-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-advances-tak-861-to-phase-iii-for-narcolepsy-type-1-following-positive-phase-iib-results 2024-02-09T13:51:12+00:00 weekly 0.7 https://trial.medpath.com/news/oral-serds-a-new-hope-for-metastatic-breast-cancer-treatment 2024-02-07T19:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/byondis-advances-novel-her2-targeting-adc-trastuzumab-duocarmazine-in-multiple-cancer-indications 2024-02-07T18:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-advances-lsd-development-program-for-major-depressive-disorder-treatment 2024-02-07T18:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/cytomx-therapeutics-reports-promising-interim-phase-1-data-for-cx-2051-antibody-drug-conjugate 2024-02-07T16:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-efficacy-and-safety-of-iptacopan-in-pnh-with-anaemia 2024-02-07T13:56:30+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-launches-brca-testing-program-for-jewish-community-to-combat-cancer-risk 2024-02-07T03:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-latozinemab-breakthrough-therapy-designation-for-frontotemporal-dementia-due-to-a-progranulin-gene-mutation-ftd-grn 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lb-pharmaceuticals-advances-schizophrenia-treatment-with-lb-102 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-upgraded-to-buy-on-successful-trial-by-investing-com 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-status-to-vepdegestrant-for-er-her2-metastatic-breast-cancer 2024-02-06T18:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-clinical-trials-regulation-advances-harmonization-with-2025-transition-deadline 2024-02-06T04:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/metagenomi-aims-for-87m-ipo-to-advance-novel-gene-editing-platform 2024-02-06T00:05:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-bnt325-db-1305-for-platinum-resistant-ovarian-cancer 2024-02-05T22:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-nipocalimab-shows-promise-in-treating-autoimmune-diseases 2024-02-05T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-treatment-niaid-national-institute-of-allergy-and-infectious 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-recommends-new-standards-for-pulse-oximeters-amid-bias 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aviceda-begins-part-2-of-phase-ii-iii-trial-for-geographic-atrophy 2024-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-announces-fda-granted-orphan-drug 2024-02-01T16:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/proniras-secures-4-65-in-series-b-financing 2024-02-01T15:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-hope-for-blood-cancer-patients 2024-02-01T12:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/merck-signals-continued-pursuit-of-15b-deals-to-offset-future-keytruda-patent-loss 2024-02-01T03:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-use-of-fedratinib-for-myelofibrosis-following-ruxolitinib-failure 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/usher-syndrome-market-insight-epidemiology-and-market-forecast-2034 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-clinical-trial-is-launched-for-a-novel-drug-that-could-extend 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-announces-u-s-fda-acceptance-of-biologics-license-application-for-afami-cel 2024-01-31T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-advances-zilebesiran-to-phase-3-cardiovascular-outcomes-trial-following-positive-kardia-3-results 2024-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/curiteva-receives-fda-clearance-for-world-s-first-3d-printed-trabecular-peek-lumbar-fusion-system 2024-01-30T12:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-neoimmunetech-s-nt-i7-for-advanced-pancreatic-cancer-treatment 2024-01-30T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/scandion-oncology-reports-positive-phase-iia-data-in-corist-part-3-trial 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-pain-drug-may-offer-alternative-to-opioids-for-acute-pain-study-finds-cnn 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-high-dose-eylea-8mg-aflibercept-accepted-for-review-by-china-s-nmpa-following-uk-approval 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-rise-therapeutics-rheumatoid-arthritis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-fda-acceptance-for-substantive-review-of-the-premarket-approval-application-for-alfapump-r-in-recurrent-or-refractory-ascites-due-to-liver-cirrhosis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-in-reversing-age-related-metabolic-dysfunction 2024-01-28T17:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-trials-restore-hearing-to-children-born-deaf 2024-01-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bravyl-shows-promise-in-slowing-als-progression-study-finds 2024-01-26T12:24:54+00:00 weekly 0.7 https://trial.medpath.com/news/major-pharma-giants-unite-at-biophysics-for-drug-discovery-summit-to-advance-novel-therapeutic-development 2024-01-26T06:06:32+00:00 weekly 0.7 https://trial.medpath.com/news/ema-confirms-recommendation-for-non-renewal-of 2024-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/generative-ai-set-to-transform-life-sciences-industry-in-2024-from-trust-building-to-personalized-medicine 2024-01-25T02:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-glioblastoma-treatment-research-at-mayo-clinic 2024-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-shows-significant-survival-benefit-in-adjuvant-therapy-for-kidney-cancer 2024-01-24T13:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/experts-outline-new-approaches-to-combination-therapy-in-atopic-dermatitis-management 2024-01-23T06:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-eflornithine-for-adult-pediatric-patients-with 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-nivolumab-plus-ipilimumab-shows-benefit-in 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/taiho-oncology-announces-publication-of-final-results-from-ascertain-clinical-trial 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/you-become-so-strong-duncan-b-c-family-enrolls-infant-son-in-clinical-trial-to-treat-leukemia 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-s-lb-100-shows-promise-in-multiple-cancer-indications-through-novel-pp2a-inhibition 2024-01-22T09:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-ramucirumab-shows-promise-in-expanding-treatment-portfolio-for-laryngeal-cancer 2024-01-22T08:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-crizotinib-explores-new-frontier-in-her2-negative-breast-cancer-treatment 2024-01-22T08:56:56+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-phase-3-trial-testing-sacituzumab-tirumotecan-pembrolizumab-combination-in-high-risk-triple-negative-breast-cancer 2024-01-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/superbug-crisis-phage-therapy-offers-hope-against-antibiotic-resistance 2024-01-21T15:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-presents-data-of-glecirasib-in-patients-with-pancreatic 2024-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stemcell-technologies-expands-clinical-capabilities-through-strategic-acquisitions-of-sqz-biotechnologies-and-propagenix 2024-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/domvanalimab-combination-shows-promise-in-first-line-gastroesophageal-cancer-treatment 2024-01-18T17:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-neurosigma-s-second-generation-monarch-etns-system-for-pediatric-adhd-treatment 2024-01-18T05:26:02+00:00 weekly 0.7 https://trial.medpath.com/news/early-treatment-in-weeks-after-hiv-infection-may-help-better-control-virus-long-term-study-finds-euronews 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pepromene-bio-inc-announces-complete-remission-of-the-cohort-1-first-patient-treated-for-relapsed-and-refractory-b-cell-acute-lymphoblastic-leukemia-b-all-in-the-phase-1-clinical-trial-of-pmb-ct01-baffr-car-t-cells-at-city-of-hope 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-drug-offers-kinder-alternative-to-chemotherapy-for-children 2024-01-17T01:15:24+00:00 weekly 0.7 https://trial.medpath.com/news/video-faricimab-shows-good-visual-stability-extended-healio 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-provides-positive-phase-2-clinical-updates-for-lead 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-bacteriophage-therapy-summit-to-address-clinical-development-challenges-in-boston 2024-01-16T08:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-crispr-gene-editing-treatment 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-receives-u-s-fda-fast-track-designation-for-nx-5948 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-of-crinecerfont-shows-promise-in-treating-pediatric-congenital-adrenal-hyperplasia 2024-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-protein-based-blood-test-achieves-90-accuracy-in-detecting-early-stage-cancers-across-18-tumor-types 2024-01-14T18:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilars-in-2024-market-evolution-promises-cost-savings-amid-industry-challenges 2024-01-14T05:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-pharmaceuticals-reports-strong-financial-growth-and-advances-in-rnai-therapeutics 2024-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-trends-from-jp-morgan-2024-m-a-revival-ai-integration-and-adc-renaissance-in-pharma 2024-01-12T07:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-study-supports-second-line-axi-cel-in-r-r-lbcl-targeted-oncology 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rh5-1-matrix-m-vaccine-shows-promising-efficacy-against-malaria-in-african-children 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nafdac-launches-electronic-clinical-trial-application-platform 2024-01-11T09:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/life-sciences-real-estate-sector-faces-four-key-challenges-in-2024-sustainability-funding-and-market-evolution 2024-01-11T01:59:15+00:00 weekly 0.7 https://trial.medpath.com/news/study-evaluates-impact-of-adjuvant-chemotherapy-on-ipmn-derived-pancreatic-ductal-adenocarcinoma 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-european-medicines-agency-s-scientific-advisory-group 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-confirms-safety-and-efficacy-of-houtou-jianweiling-tablet-for-chronic-non-atrophic-gastritis 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-antibodies-promising-advances-amid-adoption-challenges-in-cancer-treatment 2024-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmather-sets-august-2025-fda-approval-goal-date-for-ketamine-product-confirms-full-funding-through-commercial-launch 2024-01-10T12:32:36+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-advanced-technologies-reshape-clinical-trial-design-and-development-strategy 2024-01-10T04:13:59+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-advances-global-vaccine-development-with-protein-based-platform-and-matrix-m-technology 2024-01-10T02:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/five-key-pharma-marketing-trends-reshaping-industry-strategy-in-2024 2024-01-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-s-eli-002-cancer-vaccine-shows-promising-results-in-phase-1-trial-for-pancreatic-and-colorectal-cancer 2024-01-10T00:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-first-ustekinumab-biosimilar-uzpruvo 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-iii-prostact-global-study-of 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adoption-of-total-neoadjuvant-therapy-in-the-treatment 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/largest-study-to-date-of-high-dose-methotrexate-associated 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adimab-announces-2023-clinical-pipeline-update-with-12-new-partner-programs 2024-01-09T19:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/quanthealth-secures-17m-series-a-funding-to-advance-ai-powered-clinical-trial-simulations 2024-01-09T02:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-acquires-aiolos-bio-for-1-4b-expanding-asthma-treatment-portfolio-with-novel-tslp-inhibitor 2024-01-09T01:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-highlights-adverse-events-associated-with-lenvatinib-use 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-s-mazdutide-achieves-phase-3-success-in-chinese-obesity-trial-paving-way-for-first-glp-1r-gcgr-dual-agonist-approval 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genascence-advances-first-gene-therapy-for-knee-osteoarthritis-in-phase-1b-donatello-trial 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-nda-for-sh-105-in-breast-and-ovarian-cancer 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-s-amvuttra-shows-significant-cardiac-benefits-in-attr-amyloidosis-patients-at-acc-25 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-shows-promising-results-in-advanced-urothelial-carcinoma-treatment-at-2024-esmo-congress 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-for-weight-loss-in-overweight-and-obese-individuals-without-diabetes 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mobile-application-reduces-opioid-misuse-after-cesarean-section 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-post-exposure-prophylaxis-shows-promise-in-reducing-stis-among-msm 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-biib-eisai-s-drug-update-nvax-gains-on-deal-amendment 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/biolinerx-ltd-nasdaq-blrx-q3-2023-earnings-call-transcript 2024-01-08T20:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-covid-vaccines-ok-d-by-fda-escaped-convict-search-5-things-podcast 2024-01-08T15:45:22+00:00 weekly 0.7 https://trial.medpath.com/news/geovax-labs-inc-nasdaq-govx-q3-2023-earnings-call-transcript 2024-01-08T13:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/revolution-medicines-inc-nasdaq-rvmd-q3-2023-earnings-call-transcript 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/atai-life-sciences-nv-reports-q3-2023-financial-results-and-pipeline-progress 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-aldx-evlo-down-on-setback-srrk-offers-updates-more 2024-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-novo-nordisk-stocks-soar-after-weight-loss-drug-trial-boosts-outlook 2024-01-08T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-updates-on-pipeline-progress-and-corporate-developments 2024-01-08T12:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-bmy-nsclc-drug-application-gets-ema-validation 2024-01-08T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/noddy-holders-secret-throat-cancer-battle-as-wife-reveals-singer-was-told-he 2024-01-08T11:10:10+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-advances-fg001-development-for-cancer-surgery-precision 2024-01-08T11:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/inspira-iinn-advances-foothold-in-europe-with-extended-deal 2024-01-08T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-announces-preliminary-unaudited-2023-revenue-and-2024-objectives 2024-01-08T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-gains-market-research-findings-to-guide-us-commercial-strategy 2024-01-08T08:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-highlights-2023-achievements-and-plans-for-2024 2024-01-08T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-acquires-ambrx-for-2b-to-expand-antibody-drug-conjugate-portfolio-in-oncology 2024-01-08T01:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-soligenix-orphan-drug-designation-for-dusquetide-in-behcet-s-disease-treatment 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-lutikizumab-shows-promise-in-phase-2-trial-for-hidradenitis-suppurativa-advances-to-phase-3 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-outlines-2024-strategic-priorities-with-focus-on-cancer-and-autoimmune-diseases 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/curevo-vaccine-announces-positive-phase-2-trial-results-for-next-generation-shingles-vaccine 2024-01-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-disrupts-drug-access-with-lillydirect-new-telehealth-platform-for-obesity-and-chronic-disease-medications 2024-01-07T00:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-announces-preliminary-2023-revenue-and-2024-financial-guidance 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-unveils-vision-2030-strategic-roadmap 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-application-submitted-for-journey-medicals-rosacea-candidate 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acupuncture-shows-promise-in-treating-combat-related-ptsd 2024-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-therapeutics-pivots-strategy-with-pipeline-restructuring-and-22-workforce-reduction 2024-01-05T15:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/combat-veterans-took-a-psychedelic-drug-for-ptsd-then-this-happened 2024-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-workforce-reduction-and-research-pause 2024-01-04T17:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-s-ab-1005-gene-therapy-for-parkinsons-disease-meets-primary-endpoint-in-phase-ib-trial 2024-01-04T13:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/newamsterdam-pharma-announces-2024-strategic-priorities-and-clinical-trial-updates 2024-01-04T13:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/quanta-therapeutics-advances-kras-directed-drug-candidates-with-fda-ind-clearance 2024-01-04T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-advances-obecabtagene-autoleucel-car-t-therapy-for-relapsed-refractory-all 2024-01-04T10:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/patient-voice-amplification-critical-for-clinical-trial-success-industry-analysis-shows-85-retention-failure-rate 2024-01-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accords-bla-for-its-ustekinumab-stelara-r-biosimilar-accepted-by-fda-settlement-with-janssen-permits-launch-by-15-may-2025-pearce-ip 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-outlines-strategic-priorities-and-outlook-for-2024-and-2025 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upstream-bio-advances-verekitug-into-phase-2-trials-for-severe-asthma-and-chronic-rhinosinusitis-with-nasal-polyps 2024-01-03T12:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-drug-market-surges-major-pharma-companies-race-to-develop-novel-treatments 2024-01-03T02:13:03+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-to-present-at-two-upcoming-investor 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/henlius-to-release-clinical-data-at-2024-asco-gi 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-lung-cancer-therapy-succeeds-in-head-to-head-study-with-lcfa 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spero-therapeutics-initiates-phase-3-trial-for-first-oral-carbapenem-in-us-targeting-complicated-utis 2024-01-02T13:42:43+00:00 weekly 0.7 https://trial.medpath.com/news/pasithea-therapeutics-announces-fda-acceptance-of-ind-application-for-pas-004-in-advanced-cancer-patients 2024-01-02T13:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-pharmaceuticals-announces-key-updates-and-2024-milestones 2024-01-02T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mit-develops-wireless-implantable-device-for-continuous-insulin-production-in-type-1-diabetes 2024-01-02T02:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-for-cutx-101-in-treatment-of-menkes-disease 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/apogee-s-apg777-shows-75-day-half-life-in-phase-1-trial-for-atopic-dermatitis 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pynnacle-study-rezatapopt-pynnacle-clinical-study 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sabcs-2024-highlights-advances-in-breast-cancer-treatment 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-requires-guillain-barre-syndrome-gbs-warning-in 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemotherapy-plus-camrelizumab-shows-promise-for-locally-advanced-cervical-cancer 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-intervention-treatment-in-the-first-2-weeks-following-concussion 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cryptosporidium-pi-4-k-inhibitor-edi048-is-a-gut-restricted 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-ag-receives-paediatric-investigation-plan-waiver 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/measurable-residual-disease-assessment-prior-to 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-bio-announces-positive-fda-notice-for 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pirtobrutinib-shows-high-response-rates-in-relapsed-cll-patients-with-btk-mutations 2023-12-28T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-submits-premarket-approval-application-to-us-fda-for 2023-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-assisted-colonoscopy-boosts-adenoma-detection-rate-by-40-in-junior-endoscopists 2023-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-phase-3-mariposa-study-meets-primary 2023-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bms-acquires-karuna-therapeutics-for-14-billion-betting-on-novel-schizophrenia-drug-karxt 2023-12-23T08:49:46+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-issues-complete-response-globenewswire 2023-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fujirebio-launches-automated-ptau-217-plasma-assay-for-alzheimer-s-disease-research 2023-12-22T17:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-egfr-mutated-non-small-cell-lung-cancer-treatment 2023-12-22T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-advances-to-phase-ii-trial-for-cs-aki-treatment-in-turkey 2023-12-21T12:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-market-set-for-major-expansion-in-2024-ophthalmology-and-immunology-lead-growth 2023-12-21T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-advances-microbiome-therapeutics-in-oncology 2023-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-therapeutics-ceo-updates-on-phase-2-clinical-trials-progress 2023-12-20T11:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-radium-223-dichloride-expands-treatment-horizons-for-metastatic-prostate-cancer 2023-12-20T10:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-treatment-landscape-shows-improved-survival-in-metastatic-colorectal-cancer 2023-12-20T10:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-reports-preliminary-data-from-ftd-grn-gene-therapy-trial 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093-gsk 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridging-therapy-responses-may-outcomes-with-axi-cel 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/depression-and-cancer-how-psilocybin-from-mushrooms-can-help 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/revive-therapeutics-advances-bucillamine-development-for-long-covid-treatment-through-manufacturing-partnership 2023-12-18T12:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/ai-text-analytics-revolutionizes-clinical-trial-data-processing-and-patient-assessment 2023-12-18T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-drug-sunvozertinib-shows-record-61-response-rate-against-rare-lung-cancer 2023-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-lenvatinib-fails-to-meet-survival-endpoints-in-advanced-endometrial-cancer 2023-12-15T16:02:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-merck-s-welireg-for-advanced-kidney-cancer-expanding-treatment-options 2023-12-15T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/nihr-hosts-expert-panel-on-advancing-equality-and-diversity-in-clinical-research 2023-12-15T09:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-secures-two-key-patent-victories-for-parkinson-s-drug-nuplazid 2023-12-14T02:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/checkmate-77t-trial-shows-perioperative-nivolumab-significantly-improves-event-free-survival-in-resectable-nsclc 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-tigris-trial-update 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-initiates-phase-2a-trial-of-first-in-class-nlrp3-inhibitor-ht-6184-for-lower-risk-myelodysplastic-syndromes 2023-12-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-eflornithine-to-reduce-risk-of-relapse-in 2023-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/talquetamab-dose-reductions-maintain-efficacy-while-reducing-toxicities-in-relapsed-refractory-multiple-myeloma 2023-12-12T15:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/gc-biopharma-secures-44-million-who-flu-vaccine-contract-and-partners-with-canadian-firm-for-mrna-development 2023-12-12T10:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/plexium-advances-first-in-class-ikzf2-degrader-plx-4545-into-phase-1-clinical-trial 2023-12-12T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-strengthens-patent-protection-for-pirepemat-a-novel-parkinson-s-fall-prevention-therapy 2023-12-12T06:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/hope-3-trial-of-dmd-therapy-cap-1002-to-continue-as-planned 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-clinical-trial-of-car-t-cell-therapy-with-new 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/second-line-axi-cel-prolongs-survival-over-standard 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iptacopan-yields-hematological-improvements-in-pnh-persistent-anemia 2023-12-11T18:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-s-annamycin-shows-36-complete-response-rate-in-aml-phase-1b-2-trial-with-zero-cardiotoxicity 2023-12-11T13:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-study-for-adjuvant-treatment-of-non-small-cell-lung-cancer 2023-12-11T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-combination-therapy-achieves-superior-mrd-negativity-rates-in-newly-diagnosed-multiple-myeloma 2023-12-11T03:22:20+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-advances-two-novel-b-cell-lymphoma-therapies-in-first-in-human-trials 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-self-sampling-based-cervical-cancer-screening-strategy-during-covid-19-pandemic 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-herbal-injections-combined-with-platinum-based-chemotherapy-improve-outcomes-in-advanced-non-small-cell-lung-cancer 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/taiho-oncology-presents-real-world-study-data-on-oral-decitabine-and-cedazuridine-for-mds 2023-12-10T15:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/updated-odronextamab-data-from-relapsed-refractory-diffuse-globenewswire 2023-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-plus-chemotherapy-shows-sustained-survival-benefit-in-early-stage-tnbc 2023-12-09T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-advances-real-world-evidence-integration-in-drug-development-and-regulatory-decision-making 2023-12-08T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/solid-biosciences-sldb-dmd-drug-gets-fast-track-tag-stock-up 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-rare-cancer-treatment-through-home-run-clinical-trials 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-to-present-data-of-kras-g12c-inhibitor-glecirasib-in 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-grants-priority-review-for-elafibranor-a-potential-new-treatment-for-primary-biliary-cholangitis 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-receives-fda-approval-for-fabhalta-r-iptacopan-offering-superior-hemoglobin-improvement-in-the-absence-of-transfusions-as-the-first-oral-monotherapy-for-adults-with-pnh-novartis 2023-12-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-tar-200-breakthrough-therapy-designation-for-bcg-unresponsive-nmibc 2023-12-05T17:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-biosciences-receives-breakthrough-therapy-designation-from-u-s-food-and-drug-administration-for-crinecerfont-in-congenital-adrenal-hyperplasia 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brainchild-bio-spins-out-of-seattle-children-s-to-develop 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-advances-filspari-toward-fda-approval-following-pre-nda-meeting 2023-12-04T21:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-announces-positive-results-from-phase-1a-1b-clinical-trial-of-zelnecirnon-for-atopic-dermatitis 2023-12-04T20:51:36+00:00 weekly 0.7 https://trial.medpath.com/news/roche-acquires-carmot-therapeutics-for-2-7-billion-to-enter-obesity-drug-market 2023-12-04T11:13:58+00:00 weekly 0.7 https://trial.medpath.com/news/bms-advances-ipilimumab-development-for-metastatic-pancreatic-adenocarcinoma 2023-12-04T08:58:58+00:00 weekly 0.7 https://trial.medpath.com/news/elevidys-makes-history-as-first-gene-therapy-for-dmd-but-challenges-remain 2023-12-04T07:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/novel-treatment-landscape-expands-for-uveal-melanoma-with-multiple-promising-therapies-in-development 2023-12-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-asia-congress-2023-oncologypro 2023-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-outcomes-for-high-risk-non-muscle-invasive-bladder-cancer-with-pd-l-1-inhibitors 2023-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-rising-importance-of-real-world-data-and-evidence-in-pharmaceutical-r-d 2023-11-30T23:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-secures-1-3-billion-deal-with-chong-kun-dang-for-hdac6-inhibitor-targeting-cmt-disease 2023-11-30T20:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-launches-phase-3-compass-pws-trial-for-carbetocin-nasal-spray-in-prader-willi-syndrome 2023-11-30T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-s-64cu-sar-bispsma-shows-promise-in-detecting-prostate-cancer-recurrence-in-cobra-trial 2023-11-30T00:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/cretostimogene-grenadenorepvec-monotherapy-first-cg-oncology 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fresenius-kabi-and-formycon-announce-fda-submission-for-fyb202-a-ustekinumab-biosimilar-candidate 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-janssen-join-wearable-maker-to-measure-scratching-and-other-health-tech-news 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/an-anti-aging-drug-for-dogs-may-be-on-the-market-as-soon-as-2026-cbs-los-angeles 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncosil-initiates-pancosil-trial-testing-percutaneous-delivery-of-radioactive-microparticles-for-pancreatic-cancer 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-cas9-technology-revolutionizes-car-t-cell-therapy-enhancing-efficacy-and-overcoming-treatment-barriers 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-inflammation-disease-focused-acelyrin-stock-trading-lower-today-markets-insider 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-blenrep-outperforms-in-phase-iii-multiple-myeloma-trial 2023-11-27T08:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/rpt193-demonstrates-greater-improvements-in-clinical 2023-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-transformative-potential-of-immunotherapy-for-glioblastoma-patients 2023-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dxvx-advances-licensing-deal-for-ovm-200-cancer-vaccine-in-asian-markets 2023-11-24T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-secures-kras-g12d-inhibitor-in-419m-deal-with-usynova 2023-11-23T08:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iib-trial-evaluates-efficacy-and-safety-of-anyu-peibo-capsules-for-major-depressive-disorder 2023-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-health-measures-gain-traction-in-value-based-healthcare-despite-implementation-challenges 2023-11-21T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-announces-fda-approval-of-ind-application-for-car-t-nxc-201-enabling-u-s-patient-dosing-biospace 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/connect-biopharma-partners-with-simcere-for-rademikibart-development-in-greater-china 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aimovig-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-first-head-to-head-migraine-prevention-study 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/final-data-from-phase-iia-corist-part-2-trial-shows-promising-median-overall-survival-of-10-4-months 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promis-neurosciences-initiates-phase-1a-clinical-trial-for-alzheimer-s-disease-treatment 2023-11-20T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-showcases-significant-data-updates-from-kisqali-r-iptacopan-and-scemblix-r-at-sabcs-and-ash 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eptinezumab-demonstrates-sustained-long-term-efficacy-in-treatment-resistant-migraine-patients-over-18-months 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asx-health-stocks-4dx-jumps-15pc-after-fda-clearance 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/outstanding-12-month-first-in-human-data-from-xeltis-axess 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-medtronic-s-minimally-invasive-device-for-hypertension-treatment 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-approves-world-s-first-crispr-gene-therapy-for-sickle-cell-disease-and-b-thalassemia 2023-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biocon-biologics-secures-uk-approval-for-aflibercept-biosimilar-yesafili-expanding-european-market-access 2023-11-15T10:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/gene-editing-therapy-shows-promise-for-cholesterol-reduction-in-early-trial 2023-11-15T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-secures-world-first-nhs-partnership-for-inclisiran-population-health-management 2023-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nimmune-biopharma-presents-positive-first-in-human-data-of-nim-1324-at-acr-convergence-2023 2023-11-14T13:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-presents-new-data-on-safety-and-efficacy-of-zolgensma-in-older-and-heavier-children-with-sma 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elafibranor-shows-significant-efficacy-in-phase-iii-trial-for-primary-biliary-cholangitis 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-prospects-drop-after-phase-iii-ovarian-cancer-trial 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/padcev-and-keytruda-double-bladder-cancer-survival 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-and-mmv-develop-novel-malaria-treatment-for-infants-under-5kg-addressing-critical-treatment-gap 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-challenges-over-100-drug-delivery-device-patents-in-orange-book-enforcement-action 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ianalumab-achieves-primary-endpoint-in-phase-iii-itp-trial-offering-potential-for-extended-treatment-free-periods 2023-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ianalumab-becomes-first-targeted-therapy-to-show-efficacy-in-sjogren-s-disease-phase-iii-trials 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-rna-drug-zilebesiran-delivers-six-month-blood-pressure-control-with-single-injection 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/in-lung-cancer-j-j-data-amount-to-latest-salvo-against-astrazeneca 2023-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-takeda-s-adzynma-as-first-treatment-for-ultra-rare-blood-clotting-disorder-cttp 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-version-of-diabetes-drug-mounjaro-for 2023-11-08T17:59:27+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-base-editing-therapy-achieves-first-clinical-cure-of-beta-thalassaemia 2023-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-slrn-reports-q3-2023-financial-results-key-clinical-trials-progressing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/participant-engagement-and-adherence-to-providing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-biosimilar-for-stelara-that-can-treat-psorasis 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/learnings-from-real-world-evidence-of-faricimab-in-namd-and-dme-part-1 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2023-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-pioneers-ai-driven-drug-discovery-with-multimodal-transformers-and-robotic-labs 2023-11-03T06:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/lexeo-therapeutics-launches-100m-ipo-to-advance-gene-therapy-pipeline 2023-11-03T02:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-lisaftoclax-receives-fda-clearance-for-global-phase-iii-trial-in-cll-sll 2023-11-03T01:17:45+00:00 weekly 0.7 https://trial.medpath.com/news/blood-cancer-treatment-breakthrough 2023-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-s-tegoprubart-shows-promise-in-phase-1b-kidney-transplant-trial-with-superior-organ-function-preservation 2023-11-02T13:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-arexvy-dominates-rsv-vaccine-market-with-1-2b-projected-sales-outpacing-pfizer-s-abrysvo 2023-11-02T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-pharmaceuticals-stock-is-plummeting-after-biotech-benzinga 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kisqali-shows-enhanced-efficacy-in-younger-breast-cancer-patients-with-33-risk-reduction 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-advances-pediatric-asciminib-trial-for-chronic-myeloid-leukemia-with-novel-dosing-strategy 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alfasigma-acquires-galapagos-jak-inhibitor-jyseleca-in-eur170-million-deal 2023-11-01T00:48:28+00:00 weekly 0.7 https://trial.medpath.com/news/endpoints-for-clinical-trials-in-ophthalmology 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-postexposure-prophylaxis-for-prevention 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-voquezna-r-vonoprazan-tablets-for-erosive-gerd-treatment 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novartis-cosentyx-r-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-teprotumumab-in-patients-with-thyroid-eye-disease 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-srpt-to-seek-approval-for-dmd-therapy-even-after-drug-trial-failed-bloomberg 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-protac-vepdegestrant-shows-promise-for-esr1-mutant-breast-cancer-in-phase-2-trial 2023-10-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-expands-edg-5506-clinical-program-with-new-duchenne-trial-for-gene-therapy-recipients 2023-10-27T16:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-s-resminostat-receives-orphan-drug-designation-from-the-european 2023-10-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mirikizumab-omvoh-for-ulcerative-colitis 2023-10-26T22:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-plans-to-submit-bla-for-subcutaneous-lecanemab-following-promising-results 2023-10-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-supports-amivantamab-plus-lazertinib-over 2023-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-santhera-s-drug-for-rare-muscular-dystrophy 2023-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-biomarkers-drive-precision-medicine-evolution-industry-experts-predict-54b-gene-therapy-market-by-2029 2023-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-plus-chemotherapy-significantly-improves-outcomes-in-resectable-non-small-cell-lung-cancer 2023-10-23T12:46:11+00:00 weekly 0.7 https://trial.medpath.com/news/nervgen-pharma-receives-fast-track-designation-for-nvg-291-in-spinal-cord-injury-treatment 2023-10-23T12:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/dostarlimab-shows-superior-survival-outcomes-across-multiple-endometrial-cancer-molecular-subgroups-in-phase-3-ruby-trial 2023-10-23T01:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/verve-therapeutics-announces-clearance-of-investigational-new-drug-application-by-the-u-s-fda-for-verve-101-in-patients-with-heterozygous-familial-hypercholesterolemia 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-pluvictotm-shows-clinically-meaningful-and-highly 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-bispecific-immunotherapy-shows-promise-across-multiple-cancer-types-in-early-clinical-trial 2023-10-19T15:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-daiichi-sankyo-form-22-billion-alliance-for-three-novel-antibody-drug-conjugates 2023-10-19T04:41:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-rise-therapeutics-ind-application-to-initiate-a-phase-1 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-leads-to-high-pfs-rates-in-patients-with-multiple-myeloma 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-reports-positive-long-term-data-for-alfapump-in-treating-ascites 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bimzelx-r-approved-by-the-u-s-fda-for-the-treatment-of-adults-with 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/traverse-biotech-has-been-awarded-a-phase-i-sbir-grant-from-the-national-cancer-institute-to-develop-targeted-immunotherapy-for-selected-solid-tumors-biospace 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-seastar-medical-s-selective-cytopheretic-device-breakthrough-device-designation-for-hepatorenal-syndrome 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-new-real-world-data-guidance-streamlining-drug-development-and-regulatory-approval 2023-10-17T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/nucleus-radiopharma-secures-56m-series-a-to-expand-radiopharmaceutical-manufacturing-network 2023-10-17T10:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-to-offer-new-curative-treatment-for-aggressive-blood-cancer 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-receives-fda-clearance-of-tactiflextm-ablation 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/concept-medical-received-fda-ide-approval-for 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sillajen-presents-clinical-study-overview-of-anticancer-drug-bal0891-at-international-symposium 2023-10-16T16:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-nivolumab-shows-significant-benefit-in-resected-stage-iib-c-melanoma 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-completes-3rd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tilray-medical-supports-new-clinical-trial-to-study-medical-cannabis-in-glioblastoma-cancer-treatment 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-mrna-based-cancer-vaccines 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-announces-opening-of-tigris-clinical-trial-site-at-the-mayo-clinic-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-ventilation-strategies-on-pulmonary-and-cardiovascular 2023-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brain-tumor-center-stanford-medicine 2023-10-12T12:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/cap-1002-parent-project-muscular-dystrophy 2023-10-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intranasal-epinephrine-spray-shows-superior-pharmacokinetics-to-autoinjector-in-anaphylaxis-treatment-study 2023-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-positions-life-sciences-sector-for-global-leadership-with-strategic-five-point-plan 2023-10-10T21:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/crinecerfont-shows-promise-in-treating-children-with-congenital-adrenal-hyperplasia 2023-10-10T16:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/cuba-advances-phase-iii-clinical-trial-of-jusvinza-for-rheumatoid-arthritis-treatment 2023-10-09T15:25:05+00:00 weekly 0.7 https://trial.medpath.com/news/analysis-of-sodium-phenylbutyrate-and-taurursodiol 2023-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rg6501-shows-rapid-improvement-in-retinal-structure-for-geographic-atrophy-patients 2023-10-08T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-and-bristol-myers-squibb-collaborate-to-build-a-new-model-for-clinical-trials 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-votes-sufficient-evidence-available-to-support 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-uk-biobank-study-reveals-14000-novel-gene-protein-interactions-to-transform-drug-discovery 2023-10-05T02:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/expanded-access-programs-bridging-the-gap-between-clinical-trials-and-patient-need 2023-10-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-improve-blood-sugar-control-and-weight-loss-over-3-years-study-finds 2023-10-03T14:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-acquires-point-biopharma-for-1-4-billion-to-expand-radioligand-therapy-portfolio 2023-10-03T05:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-2023-2024-covid-19-vaccine-authorized-for-emergency-use-in-the-u-s 2023-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/valbiotis-sa-phase-ii-iii-reverse-it-study-to-be-presented-at-2023-easd-congress 2023-10-02T17:42:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-greenlights-alzamend-neuro-s-phase-iia-trial-of-novel-lithium-therapy-al001-for-bipolar-disorder 2023-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-advancement-prospects-plunge-for-parkinsons 2023-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapies-for-diffuse-midline-glioma-sciencedirect 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-immune-checkpoint-inhibition-for-hepatocellular-carcinoma-treatment 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nxc-201-demonstrates-feasibility-of-bcma-directed-car-t-cell-therapy-in-relapsed-refractory-al-amyloidosis 2023-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-exxua-a-novel-antidepressant-for-major-depressive-disorder 2023-09-28T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/akebia-therapeutics-resubmits-new-drug-application-to-the-fda-for-vadadustat 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-emergency-use-authorization-for-evusheld 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-cancer-drug-combo-beats-tagrisso-in-closely-watched-trial 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bosutinib-for-pediatric-chronic-myelogenous-leukemia-patients 2023-09-27T18:39:45+00:00 weekly 0.7 https://trial.medpath.com/news/viva-s-portfolio-companies-announce-significant-advances-in-biopharmaceutical-innovations 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-announces-48-week-results-from-phase-2-envision-study-of-ubx1325-in-patients-with-wet-age-related-macular-degeneration 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amphista-therapeutics-hits-second-milestone-in-bristol-myers-squibb-protein-degradation-partnership 2023-09-26T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-optimizes-xanamia-phase-2b-alzheimer-s-disease-trial-design 2023-09-26T12:56:06+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-starts-the-pivotal-clinical-trial-for-axess 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-receives-orphan-drug-designation-odd-for-resminostat-kinselby 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-targets-and-strategic-sequencing-the-evolving-landscape-of-t-cell-redirection-therapies-in-multiple-myeloma 2023-09-22T13:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-hasten-tool-accelerates-virtual-drug-screening-10-fold 2023-09-22T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/leucid-bio-s-lateral-nkg2d-car-t-therapy-leu011-receives-mhra-approval-for-solid-tumor-clinical-trial 2023-09-21T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/drug-for-rare-kidney-disease-narrowly-misses-mark-in-clinical-trial 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-immix-biopharma-nxc-201-as-a-treatment-for-amyloid-light-chain-al-amyloidosis-september-21-2023-at-08-56-am-edt-marketscreener 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-roactemra-biosimilar-tyenne-receives-eu-approval-marking-milestone-for-fresenius-kabi 2023-09-20T02:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/extended-course-nirmatrelvir-ritonavir-shows-promise-in-treating-long-covid-symptoms 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musks-neuralink-recruiting-humans-to-trial-brain-implant 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/translarna-approval-for-dmd-in-eu-not-recommended-for-renewal-therapy-developer-ptc-to-seek-new-review-by-ema-committee-muscular-dystrophy-news 2023-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cloud-based-data-analytics-emerges-as-key-driver-for-life-sciences-innovation-and-drug-development 2023-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genetically-modified-pig-kidney-functions-for-61-days-in-human-body-setting-xenotransplantation-record 2023-09-14T15:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-phase-2b-3-trial-of-blarcamesine-shows-promising-results-in-alzheimer-s-disease-treatment 2023-09-14T11:30:11+00:00 weekly 0.7 https://trial.medpath.com/news/axicabtagene-ciloleucel-as-second-line-therapy-in-large-b-cell-lymphoma 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/game-changing-alzheimer-s-drugs-could-drive-a-wave-of 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-combo-covid-19-and-flu-vaccine-shows-promising-results-in-early-trial 2023-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-skyrizi-r-risankizumab-met-all-primary-and-secondary-endpoints-versus-stelara-r-ustekinumab-in-head-to-head-study-in-crohn-s-disease 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/izokibep-fails-in-phase-2b-3-hidradenitis-suppurativa-trial 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-plummets-on-skin-disease-trial-schaeffer-s-investment-research 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-nasdaq-slrn-plummets-on-disappointing-hs-trial-results-tipranks-com 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-as 2023-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-alzheimer-s-disease-treatment-a-focus-on-disease-modifying-therapies 2023-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotech-faces-steep-decline-bank-of-america-warns 2023-09-08T14:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/ariceum-therapeutics-doses-first-patient-in-phase-ib-study-for-small-cell-lung-cancer-treatment 2023-09-07T08:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/application-to-market-givinostat-for-dmd-in-europe-under 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-inc-closes-c-6-1-million-bought-deal-convertible-note-financing-the-globe-and-mail 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/retail-pharmacies-are-working-with-pharmaceutical-companies-to 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-t-cell-engagers-show-promise-as-later-line-therapies-for-relapsed-refractory-dlbcl 2023-09-06T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/cingulate-s-phase-3-trial-shows-promising-results-for-once-daily-adhd-treatment-ctx-1301 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-2-activate-trial-of-bia-28-6156-for 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/olema-oncology-secures-up-to-180-million-in-combined-financing 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nestle-divests-palforzia-to-stallergenes-greer-exits-peanut-allergy-treatment-market 2023-09-04T02:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/denosumab-biosimilar-ly01011-demonstrates-bioequivalence-in-phase-1-trial 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mpn-628-surpass-et-ropeginterferon-alfa-2b-p1101 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-launches-phase-3-trial-testing-elranatamab-triple-combination-for-newly-diagnosed-multiple-myeloma 2023-08-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-outlook-therapeutics-wet-amd-drug-due-to-manufacturing-issues-and-insufficient-clinical-evidence 2023-08-30T13:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-names-first-10-drugs-for-price-negotiations-including-major-diabetes-and-cancer-therapies 2023-08-29T05:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/bluerock-s-phase-i-study-with-bemdaneprocel-in-parkinson-s-disease-meets-primary-endpoint 2023-08-28T10:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-first-phase-3-program-for-oral-pcsk9-inhibitor-mk-0616-to-treat-high-cholesterol 2023-08-25T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/synapticure-on-science-clinical-trials-for-sporadic-als 2023-08-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lipid-nanoparticles-demonstrate-complex-immunological-effects-in-mrna-vaccine-delivery 2023-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolution-in-pharma-transforming-drug-development-to-patient-care 2023-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genesis-therapeutics-secures-200m-series-b-to-advance-ai-powered-drug-discovery-platform 2023-08-21T12:46:52+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-of-the-launch-3-trial-comparing-laparoscopic-and-abdominal-radical-hysterectomy-for-cervical-cancer 2023-08-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/yale-researchers-develop-polymer-nanoparticles-for-effective-mrna-delivery-to-lungs 2023-08-16T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-fda-approval-for-generic-bromfenac-ophthalmic-solution-for-post-cataract-surgery-treatment 2023-08-16T15:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/immix-announces-additional-nxc-201-al-amyloidosis-data-to-be-presented-tipranks-com 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-clear-study-shows-improved-efficacy-of-lenvatinib-plus-pembrolizumab-in-advanced-renal-cell-carcinoma 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-second-line-axi-cel-for-dlbcl-hgbl-onclive 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-regulators-recommend-cabometyx-for-radioactive-iodine-refractory-thyroid-cancer-based-on-78-reduction-in-disease-progression 2023-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-reports-second-quarter-2023-financial 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-axess-vascular-graft-development-receives-funding-from-european 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drug-wegovy-cuts-heart-attack-risk-in-people-with-obesity-study-shows 2023-08-08T19:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/asco-s-guideline-rapid-recommendation-update-for-esr1-mutation-testing 2023-08-08T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-veteran-receives-fda-approved-qalsody-for-sod1-als-at-houston-va-medical-center 2023-08-07T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-announces-breakthrough-therapy-designation-pr-newswire 2023-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-avacincaptad-pegol-for-geographic-atrophy 2023-08-05T14:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-an-oral-treatment-for-postpartum-depression-called-zuranolone 2023-08-05T11:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/ugn-102-may-be-an-effective-non-surgical-option-for-bladder-cancer-subtype 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-the-endothelin-a-receptor-in-iga-nephropathy-a-new-therapeutic-approach 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cage-bio-announces-positive-topline-results-from-its-phase-2-study-on-tofacitinib-for-atopic-dermatitis 2023-08-03T14:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-could-ease-symptoms-of-children-with-adhd-wales-online 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-therapeutics-receives-fda-orphan-drug 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-announces-fda-orphan-drug-designation-for-tyra-300-for 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/obexelimab-shows-promise-in-treating-igg4-related-disease 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-cancer-detection-tool-shows-13-boost-in-prostate-cancer-diagnosis-expands-to-breast-cancer-screening-in-wales 2023-07-31T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-hcc-treatment-the-role-of-tace-combined-with-targeted-and-immune-therapies 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-long-covid-treatment-clinical-trials-from-nih-getting-underway-cbs-news 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/artificial-intelligence-enhances-diagnostic-accuracy-in-capsule-endoscopy-for-small-bowel-bleeding 2023-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-galactosemia-program 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-of-ak0529-in-respiratory-syncytial-virus-infected-infant-patients 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/samuraciclib-shows-promise-in-advanced-breast-cancer-patients-after-cdk4-6-inhibitor-failure 2023-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/update-on-rapamycin-clinical-trial-for-pc-treatment 2023-07-21T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/digital-transformation-reshapes-pharma-industry-with-30b-investment-drive 2023-07-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-vabysmo-shows-sustained-vision-improvements-with-extended-treatment-intervals-in-retinal-vein-occlusion-studies 2023-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lucas-was-facing-life-in-a-wheelchair-until-a-medical-trial-gave-his-parents-hope-abc-news 2023-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mind-diet-may-not-be-brain-boosting-in-the-short-term-new-clinical-trial-shows-cnn 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/magic-mushrooms-could-help-women-deal-with-cancer-related-depression-world-news-sky-news 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-nda-for-rivoceranib-camrelizumab-in-unresectable-hcc 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-finds-alzheimers-drug-donanemab-can-modestly-slow-memory-decline-the-new-york-times 2023-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-follow-up-data-reinforce-efficacy-of-pembrolizumab-based-combinations-in-advanced-renal-cell-carcinoma 2023-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/polyunsaturated-fats-and-als-disease-progression-cap-1002-improves-motor-function-in-dmd-lecanemab-granted-traditional-approval 2023-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-forecast-major-shifts-in-lung-cancer-treatment-immunotherapy-and-precision-medicine-lead-the-way 2023-07-13T04:44:53+00:00 weekly 0.7 https://trial.medpath.com/news/pirtobrutinib-shows-promising-efficacy-in-cll-sll-patients-after-btk-inhibitor-failure 2023-07-12T14:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults-practicaldermatology 2023-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-u-s-patients-implanted-with-innovative-fire1-remote-heart 2023-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-receives-fda-authorization-for-first-ever-phase-3-sarcopenia-trial 2023-07-10T11:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/tango-therapeutics-initiates-phase-1-2-trial-of-tng462-for-mtap-deleted-solid-tumors 2023-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-widens-door-to-research-on-psychedelics-like-ketamine-lsd-for-treatment-of-ptsd-depression-los-angeles-times 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-cap-1002-continues-to-show-preservation-of-cardiac-function-in-open-label-extension-study-of-dmd 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-care-program-shows-comparable-effectiveness-to-in-person-physiotherapy-for-chronic-low-back-pain 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sulopenem-etzadroxil-probenecid-drug-market-forecast-and-analysis-sulopenem-etzadroxil-probenecid-for-uncomplicated-urinary-tract-infection-market-size-analysis-and-competitive-landscape-by-delveinsight 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/people-with-alzheimers-urged-to-follow-fiona-phillips-and-join-drug-trials-alzheimer-s-the-guardian 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-launches-three-new-trial-sites-for-hemoperfusion-device-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-achieves-milestone-with-1000th-alfapump-implant-advances-to-heart-failure-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-leqembi-the-alzheimers-drug-approved-by-the-fda-the-new-york-times 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-announces-publication-of-claudin18-2-x-4-1bb-biospace 2023-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/margetuximab-an-active-alternative-for-later-line-therapy-in 2023-07-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-dct-draft-guidance-a-hit-or-miss 2023-07-03T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-fully-ai-generated-drug-enters-phase-ii-clinical-trials-for-idiopathic-pulmonary-fibrosis 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-the-one-step-nucleic-acid-amplification-method-for-rapid-detection-of-lymph-node-metastases-in-endometrial-cancer 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-approved-for-duchenne-muscular-dystrophy 2023-06-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-srpt-s-dmd-therapy-approval-icpt-s-setback-more-updates 2023-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hvivo-plc-develops-hmpv-human-challenge-model 2023-06-28T07:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-atogepant-shows-significant-efficacy-in-treatment-resistant-episodic-migraine-patients 2023-06-26T15:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/janssen-submits-marketing-authorisation-application-to-the 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stock-market-financialcontent-business-page 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/approved-anti-obesity-medications-in-2022-a-comprehensive-overview 2023-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-submits-fda-application-for-updated-covid-19-vaccine-targeting-xbb-variants 2023-06-22T21:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-cancer-drug-ruxolitinib-shows-promise-for-treating-cardiac-arrhythmias 2023-06-22T17:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/zanubrutinib-plus-obinutuzumab-and-venetoclax-shows-high-undetectable-mrd-rate-in-cll-sll 2023-06-22T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-complex-validation-challenges-in-atmp-analytical-methods-key-considerations-for-drug-development 2023-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-positive-outcomes-from-north-american-pivotal-alfapump-study-poseidon 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-role-of-glp-1-agonists-in-obesity 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anbalcabtagene-autoleucel-shows-84-response-rate-in-relapsed-refractory-large-b-cell-lymphoma 2023-06-20T20:26:53+00:00 weekly 0.7 https://trial.medpath.com/news/tiny-implant-has-been-proven-to-half-the-number-of-hospital-admissions-for-heart-failure-daily-mail-online 2023-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-delays-decision-on-gsk-bone-cancer-drug-acquired-in-2b-buyout 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-avita-medical-s-recell-system-for-vitiligo-skin-repigmentation 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-ag-resminostat-marketing-application-proceeding-kinselby 2023-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/olix-pharmaceuticals-initiates-phase-i-trial-for-androgenic-alopecia-treatment 2023-06-14T10:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-completes-5-million-at-the-market-equity-offering-program 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/video-real-world-data-show-good-results-of-faricimab-in-dme-healio 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-faces-setback-as-us-court-invalidates-key-myrbetriq-patent 2023-06-12T03:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-plus-chemotherapy-reduces-disease-progression-risk-by-32-in-resectable-nsclc 2023-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-in-radionuclide-therapy-for-the-treatment 2023-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/selinexor-shows-significant-survival-benefits-in-multiple-myeloma-subgroups-from-boston-trial 2023-06-09T16:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-gene-therapies-show-promise-in-early-sickle-cell-disease-trials 2023-06-09T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisers-vote-in-favor-of-infant-rsv-drug-time 2023-06-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-clinical-trials-three-key-innovations-transforming-patient-recruitment-and-retention 2023-06-07T23:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/brainchild-04-study-is-enrolling-patients-with-brain-and-spinal-cord 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/frontiers-comparative-evaluation-of-clinical-glycemic-control-markers 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-constitutional-challenge-against-medicare-drug-price-negotiations 2023-06-06T09:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-atr-inhibitor-camonsertib-shows-promise-in-dna-repair-deficient-cancers 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uromems-achieves-breakthrough-with-first-smart-artificial-urinary-sphincter-implant-in-female-patient 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-prioritizes-gsk-s-breakthrough-drug-jemperli-for-endometrial-cancer-treatment-a-first-in-decades 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-subpopulation-analysis-of-the-phase-3-arasens-study 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sensydia-secures-3m-nih-grant-to-advance-ai-based-cardiac-assessment-platform-biospace 2023-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/avutometinib-defactinib-combination-shows-45-response-rate-in-low-grade-serous-ovarian-cancer 2023-06-04T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vorasidenib-shows-promise-as-first-targeted-therapy-for-idh-mutant-low-grade-gliomas 2023-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-to-present-new-oncology-data-at-asco-2023 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-tuberous-sclerosis-drug-market-projected-to-reach-1-25-billion-by-2030-growing-at-23-1-cagr 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/varmx-secures-eur30m-series-b2-funding-to-advance-anticoagulation-reversal-drug-vmx-c001-toward-pivotal-trial 2023-06-01T09:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/nfl-biosciences-nfl-101-shows-promise-as-first-in-class-smoking-cessation-treatment-in-phase-2-trial 2023-06-01T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-acquires-belgium-based-coris-bioconcept-for-ps7-4-million-to-expand-diagnostics-portfolio 2023-06-01T05:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-in-essential-thrombocythemia-et 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-2a-clinical-trial-in-als-with-ropinirole-a-drug 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/metriopharm-s-mp1032-receives-fda-orphan-drug-designation-for-duchenne-muscular-dystrophy-treatment 2023-05-30T09:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-psma-targeted-pet-imaging-agent-for-prostate-cancer 2023-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sunlight-and-fresco-2-trials-show-promising-results-for-refractory-colorectal-cancer-treatment 2023-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/update-on-the-efficacy-of-venetoclax-for-chronic-lymphocytic-leukemia 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trial-explores-ribociclib-plus-endocrine-therapy-for-early-breast-cancer 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-data-from-phase-ib-ii-nsclc-combo-therapy-trial 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/usda-approves-first-therapeutic-treatment-for-canine-parvovirus-using-monoclonal-antibody-technology 2023-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musks-brain-implant-technology-gains-fda-approval-fox-business 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-gene-therapy-for-rare-skin-disease-but-costs-are-outrageous-cbs-colorado 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tvardi-therapeutics-to-present-phase-1-trial-data-of-stat3-inhibitor-tti-101-at-asco-2023 2023-05-25T09:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/bial-r-d-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of 2023-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vega-therapeutics-receives-fda-orphan-drug 2023-05-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/valbiotis-announces-success-of-reverse-it-clinical-study-on-totum-63 2023-05-22T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/microbiome-modulation-with-sim01-shows-promise-for-long-covid-treatment-in-randomized-trial 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-delays-in-confirmatory-studies-for-accelerated-fda-approvals 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heart-device-breakthrough-next-cochlear-stock-ebr-systems-surges-after-heart-device-breakthrough-surges-after-heart-device-breakthrough 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nexcella-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinical-trial-biospace 2023-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-two-bispecific-t-cell-engagers-for-relapsed-refractory-b-cell-lymphomas 2023-05-19T17:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-krystal-biotech-s-skin-disorder-gene-therapy 2023-05-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-clinical-trial-matching-platforms-show-promise-in-addressing-patient-recruitment-challenges 2023-05-18T02:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/satsuma-pharmaceuticals-announces-fda-acceptance-of-505-b-2-nda-for 2023-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/siren-biotechnology-unveils-promising-preclinical-data-for-novel-cancer-treatment-combining-aav-gene-therapy-with-cytokine-immunotherapy 2023-05-17T00:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/elevar-therapeutics-submits-new-drug-application-to-fda-for-combination 2023-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aging-dogs-provide-insights-for-human-longevity 2023-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-receives-regulatory-approval-to-launch-first-ever-phase-3-trial-for-sarcopenia-treatment 2023-05-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/local-news-tailored-for-you-citybiz 2023-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tucatinib-plus-trastuzumab-shows-promise-for-her2-positive-metastatic-colorectal-cancer 2023-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/skin-patch-developed-with-ucc-researchers-helps-ease-peanut-allergy-symptoms-in-toddlers-the-irish-times 2023-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/skyrocketing-popularity-puts-glp-1-agonists-for-weight-loss-on-cardiologys-radar 2023-05-12T17:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/novo-holdings-leads-200m-series-a-investment-in-windward-bio-for-advanced-respiratory-treatments 2023-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kintor-pharma-s-kx-826-shows-statistically-significant-hair-growth-in-us-phase-ii-trial-for-male-pattern-baldness 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mirocals-trial-results-low-dose-il-2-shows-potential-benefit-for-subset-of-mnd-patients 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-atezolizumab-and-bevacizumab-delays-recurrence-in-early-stage-hcc 2023-05-10T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-guidance-agenda-what-is-cder-cooking-for-clinical-trials 2023-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-trial-highlights-egfr-targeting-therapy-benefits-for-metastatic-colorectal-cancer 2023-05-08T12:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/lorlatinib-shows-promise-in-alk-driven-refractory-neuroblastoma-with-emerging-resistance-mechanisms-identified 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-safety-and-efficacy-of-mesenchymal-stem-cell-therapy-in-severe-covid-19-patients 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-in-biotech-promising-developments-in-diabetes-cancer-and-lymphoma-treatments 2023-05-04T17:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/visus-therapeutics-announces-positive-phase-3-clinical-trial-results-for-brimocholtm-pf-in-treating-presbyopia 2023-05-04T12:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/an-rsv-vaccine-has-been-approved-by-the-fda-its-a-huge-deal-vox 2023-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-trial-finds-alzheimers-drug-can-slow-progress-of-disease-the-new-york-times 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaessentia-initiates-phase-3b-trial-of 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-expands-cell-therapy-portfolio-with-new-car-t-deals 2023-05-02T12:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-in-early-alzheimer-s-disease 2023-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-brain-cancer-vaccine-survaxm-shows-promise-in-extending-glioblastoma-survival-to-26-months 2023-04-30T19:50:49+00:00 weekly 0.7 https://trial.medpath.com/news/church-based-intervention-aims-to-reduce-blood-pressure-in-african-americans 2023-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/toripalimab-combo-shows-superior-survival-over-sunitinib-in-renal-cell-carcinoma 2023-04-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iomt-set-to-transform-healthcare-with-486b-market-projection-by-2031 2023-04-28T02:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-extension-of-indications-for-nivolumab 2023-04-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-tirzepatide-shows-superior-weight-loss-results-in-diabetes-patients-fda-approval-expected-by-year-end 2023-04-27T21:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/novel-bcma-targeted-therapies-and-emerging-agents-transform-treatment-landscape-for-relapsed-refractory-multiple-myeloma 2023-04-26T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-unveils-ambitious-pharmaceutical-reform-single-market-plan-sparks-industry-debate 2023-04-26T06:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study 2023-04-26T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/dual-action-hydrogel-prevents-brain-cancer-returning-in-100-of-test-mice 2023-04-26T03:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-receives-fda-approval-for-breakthrough-als-treatment-pivotal-moment-in-als-research 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/one-week-elderberry-juice-treatment-increases-postprandial-carbohydrate-oxidation 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-for-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-04-24T20:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/leaked-data-show-cilta-cel-delivers-74-reduction-in-risk-of 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelics-may-better-treat-depression-and-anxiety-symptoms-than 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sleeping-pill-shows-potential-in-reducing-alzheimer-s-proteins 2023-04-20T14:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-botensilimab-plus-balstilimab-for-non-msi-h-dmmr-metastatic-colorectal-cancer 2023-04-20T13:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-withdraws-authorization-for-original-covid-19-vaccines 2023-04-19T18:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/second-omicron-booster-authorized 2023-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-omidubicel-for-blood-cancers-in-need-of-transplant 2023-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-leverages-ai-to-develop-novel-cdk8-inhibitor-for-cancer-treatment 2023-04-13T00:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/naxswabtm-otc-novel-naloxone-nasal-swab-successfully-administered-by-children-and-adults-to-potentially-rescue-someone-from-an-opioid-overdose-in-study 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-shows-breakthrough-results-in-advanced-acute-myeloid-leukemia-trial 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/almirall-launches-first-dermatology-study-to-assess-patient-wellbeing-as-primary-endpoint-in-psoriasis-treatment 2023-04-12T11:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/alebund-pharmaceuticals-secures-nearly-rmb-200-million-in-pre-c-round-financing 2023-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-lenvatinib-fails-to-meet-primary-endpoints-in-melanoma-and-colorectal-cancer-trials 2023-04-07T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-awards-prime-scheme-designation-to-mrna-4157 2023-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acalabrutinib-avo-triplet-therapy-in-high-risk-cll 2023-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-emergency-use-authorization-for-vilobelimab-in-treating-critically-ill-covid-19-patients 2023-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nexcella-announces-2023-haematologica-editorial-highlighting-nxc-201-efficacy-in-the-context-of-u-s-food-and-drug-administration-approved-bcma-car-t-cells-nexcella-inc 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-provides-business-and-corporate-updates-and 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/generic-manufacturers-secure-licenses-for-long-acting-hiv-prevention-drug-cabotegravir 2023-03-30T09:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/tracking-the-covid-19-vaccines-the-global-landscape 2023-03-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-enhances-immunogenicity-in-cervical-cancer-treatment 2023-03-29T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-panel-to-review-obesity-drug-liraglutide-for-essential-medicines-list 2023-03-29T14:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/nih-releases-data-showing-more-clinical-trial-sponsors-are-reporting-results-but-most-miss-deadlines 2023-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-guidelines-to-support-applications-for-accelerated-approvals 2023-03-28T19:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/thermosome-s-the001-receives-regulatory-approval-for-first-in-human-trial-in-soft-tissue-sarcoma 2023-03-28T08:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-theranostics-expands-partnership-with-genesiscare-for-phase-i-radiopharmaceutical-trials-in-australia 2023-03-27T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/kala-pharmaceuticals-provides-safety-update-and-completes-enrollment-for-chase-phase-2b-trial 2023-03-27T12:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-improves-event-free-survival-in-advanced-melanoma-patients 2023-03-23T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/olix-pharmaceuticals-receives-approval-for-phase-1-clinical-trial-of-new-hair-loss-treatment 2023-03-23T11:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/asciminib-monotherapy-in-patients-with-cml-cp-without-bcr-abl1-t315i-mutations-treated-with-at-least-two-prior-tkis-4-year-phase-1-safety-and-efficacy-results-leukemia 2023-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-introduces-new-measures-to-streamline-clinical-trial-approvals-in-the-uk 2023-03-21T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-technology-revolutionizes-rare-disease-diagnosis-reducing-detection-time-by-4-4-years 2023-03-20T02:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/nubeqatm-darolutamide-approved-for-additional-prostate 2023-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/toripalimab-combined-with-lenvatinib-and-gemox-is-a 2023-03-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-cd20-cd19-car-t-cell-therapy-shows-promising-results-in-mantle-cell-lymphoma 2023-03-16T15:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-reinstated-to-abpi-after-two-year-suspension-for-code-violations 2023-03-16T03:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-shows-promise-in-phase-1-trial-for-kmt2a-rearranged-and-npm1-mutated-acute-leukemia 2023-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sapience-therapeutics-receives-ind-clearance-from-fda-to-proceed-with 2023-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/israeli-scientists-develop-world-s-first-mrna-vaccine-against-antibiotic-resistant-bacteria 2023-03-12T07:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-to-advance-alzheimer-s-research 2023-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-health-measures-transform-patient-care-through-pre-competitive-industry-collaboration 2023-03-10T04:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-for-microcystic-lymphatic-malformations 2023-03-09T14:24:54+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-concludes-solanezumab-development-after-alzheimer-s-study-fails 2023-03-09T12:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/invox-pharma-completes-161-million-acquisition-of-f-star-therapeutics-to-strengthen-bispecific-antibody-pipeline 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-trials-for-long-covid-19-a-call-to-action 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/randomized-clinical-trial-of-neoadjuvant-therapy-for-escc-shows-promising-results 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tailored-axillary-surgery-a-novel-approach-for-clinically-node-positive-breast-cancer 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-and-msd-s-mrna-cancer-vaccine-shows-44-reduction-in-melanoma-recurrence-risk 2023-03-06T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/avo-triplet-regimen-continues-to-show-durable-responses-in-high-risk-cll 2023-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-sbla-for-traditional-approval-of-leqembi-for-alzheimer-s-disease-treatment 2023-03-05T23:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-to-establish-uk-innovation-and-technology-centre-at-harwell-science-campus-by-2025 2023-03-05T16:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-axillary-management-in-breast-cancer-therapy-a-focus-on-de-escalation-and-escalation-strategies 2023-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-deruxtecan-gains-regulatory-approvals-in-china-and-europe-for-her2-positive-cancers 2023-03-02T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impacts-of-fda-approval-and-medicare-restriction 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/omission-of-axillary-lymph-node-dissection-in-breast-cancer-patients-with-residual-nodal-disease-after-neoadjuvant-chemotherapy 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1b-clinical-trial-results-for-socazolimab-in-es-sclc-treatment 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-founded-company-develops-first-ai-designed-covid-19-drug-starts-clinical-trials 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/avutometinib-plus-defactinib-generates-responses-in 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ux111-shows-continued-dose-dependent-efficacy-as-an 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/survival-outcomes-in-braf-v600e-mutated-advanced-colorectal-cancer-chemotherapy-alone-vs-chemotherapy-combined-with-bevacizumab 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blue-lake-biotechnology-s-nasal-covid-19-vaccine-shows-86-efficacy-in-phase-1-trial 2023-02-24T20:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/study-to-evaluate-expanded-methadone-access-amid-opioid-crisis 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-completes-1-3-billion-acquisition-of-cincor-pharma-for-hypertension-drug-baxdrostat 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-still-worth-pursuing-the-repurposing-of-metformin-as-a-cancer 2023-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promius-pharma-advances-minocycline-hydrochloride-er-development-for-rosacea-treatment 2023-02-22T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alteogen-s-subsidiary-completes-phase-iii-enrollment-for-eylea-biosimilar-in-wet-amd 2023-02-22T00:34:10+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-for-sti-prevention-highly-effective-minimal-drug 2023-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-industry-braces-for-200b-patent-cliff-as-biologics-face-biosimilar-competition 2023-02-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-belantamab-mafodotin-expands-development-portfolio-to-target-diffuse-large-b-cell-lymphoma 2023-02-20T08:21:08+00:00 weekly 0.7 https://trial.medpath.com/news/novel-gene-therapies-and-biomarkers-advance-the-fight-against-frontotemporal-dementia 2023-02-20T06:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/pragmatica-lung-trial-pioneers-streamlined-approach-to-cancer-drug-development-in-advanced-nsclc 2023-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-sparing-risk-enabled-therapy-after-initiating 2023-02-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lamzede-for-alpha-mannosidosis-treatment 2023-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-adcs-and-serds-transform-breast-cancer-treatment-landscape 2023-02-15T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acr-initiatives-to-reduce-disparities-in-clinical-trials 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisers-to-consider-emergents-ebs-narcan-spray-as-otc-overdose-antidote-bloomberg 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lg-chem-completes-571-million-aveo-acquisition-to-accelerate-us-cancer-market-entry 2023-02-14T10:49:01+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-significantly-improves-survival-rates-for-operable-bladder-cancer-patients 2023-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nci-selects-two-assays-for-vanguard-study-on-multi-cancer-detection-tests 2023-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-receives-fda-approval-to-begin-study 2023-02-09T13:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/people-are-taking-a-20-cent-wonder-drug-to-slow-aging-and-lose-weight-some-doctors-say-it-s-promising 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-approaches-in-igan-treatment-the-applause-igan-study 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ezurpimtrostat-for-hcc-treatment 2023-02-08T18:58:44+00:00 weekly 0.7 https://trial.medpath.com/news/neogap-receives-approval-for-clinical-trial-cision-news 2023-02-06T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reaches-enrolment-target-for-insight-003-trial 2023-02-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-developed-car-t-cell-therapy-targeting-cd22-heads-to-clinical-trials 2023-02-03T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/major-kinase-inhibitor-summit-to-showcase-next-generation-cancer-therapeutics-advances 2023-02-02T06:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evaluation-of-ocrelizumab-in-multiple-sclerosis-shows-promising-results 2023-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/significant-advances-and-collaborations-among-viva-s-portfolio-companies 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-outcomes-of-panobinostat-in-heavily-pretreated-multiple-myeloma-patients 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsks-anemia-drug-gets-fda-nod-only-for-patients-on-dialysis-bloomberg 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rise-therapeutics-announces-fda-clearance-of-its-ind-application-to 2023-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/palbociclib-plus-endocrine-therapy-in-hormone-receptor 2023-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-elacestrant-as-first-oral-serd-for-advanced-er-her2-breast-cancer 2023-01-27T21:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-accepts-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease 2023-01-26T23:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/alleviant-medical-closes-75m-in-financing 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/january-2025-fda-brief 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelics-in-medicine-a-renaissance-in-mental-health-treatment 2023-01-25T10:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-hcp-engagement-how-life-sciences-companies-are-optimizing-commercial-success-through-data-analytics 2023-01-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-advances-pivotal-study-for-bria-imt-in-metastatic-breast-cancer-following-positive-fda-feedback 2023-01-24T14:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/artificial-intelligence-enhances-cancer-clinical-trial-enrollment-efficiency 2023-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd40-directed-sea-cd40-combo-denotes-antitumor 2023-01-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/an-alternative-dosing-strategy-for-ropeginterferon-alfa-2b 2023-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ampicillin-proves-effective-against-vre-urinary-tract-infections-despite-resistance-concerns 2023-01-17T08:16:30+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-unify-platform-revolutionizes-clinical-trials-with-precision-medicine-and-digital-innovation 2023-01-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-3-study-shows-robust-immunogenicity-of-nvx-cov2601-in-vaccine-naive-individuals-with-prior-sars-cov-2-infection 2023-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-discontinues-moxetumomab-pasudotox-for-hairy-cell-leukemia-due-to-low-clinical-uptake 2023-01-13T16:25:58+00:00 weekly 0.7 https://trial.medpath.com/news/could-this-drug-make-your-dog-live-longer-it-just-cleared-a-major 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-cgrp-targeting-therapy-for-pediatric-migraine-prevention 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ima-group-expands-clinical-research-network-with-clinical-trials-of-america-acquisition 2023-01-11T12:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-highlights-2022-achievements-and-future-plans-in-shareholder-letter 2023-01-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adimab-announces-2022-clinical-pipeline-update-with-seven-new-partner-programs 2023-01-11T05:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-summary-axicabtagene-ciloleucel-for-second-line-treatment 2023-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-novel-tkk1-therapy-for-er-her2-advanced-breast-cancer 2023-01-10T20:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-evaluates-durvalumab-for-bcg-unresponsive-bladder-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stokes-phase-3-trial-of-stk-001-for-dravet-planned-for-next-year 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/folfoxiri-plus-cetuximab-or-bevacizumab-as-first-line-treatment-for-brafv600e-mutant-metastatic-colorectal-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xbb-1-5-likely-resistant-to-evusheld-fda-says 2023-01-09T16:00:27+00:00 weekly 0.7 https://trial.medpath.com/news/14-breakthrough-drugs-poised-for-blockbuster-status-by-2027-clarivate-analysis 2023-01-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-weight-loss-effectiveness-of-glp-1-agonists-in-type-2-diabetes-patients 2023-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syros-pharmaceuticals-inc-nasdaq-syrs-q1-2023-earnings-call-transcript 2023-01-08T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/editas-medicine-inc-nasdaq-edit-q4-2022-earnings-call-transcript 2023-01-08T13:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-inc-nasdaq-aldx-q4-2022-earnings-call-transcript 2023-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pulls-eua-granted-to-astrazeneca-s-azn-evusheld 2023-01-08T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/geron-corporation-nasdaq-gern-q4-2022-earnings-call-transcript 2023-01-08T10:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-reaches-beyond-cancer-penn-bioengineering-blog 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimers-drug-lecanemab-receives-accelerated-approval-amid-safety-concerns-cnn 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combomatch-will-test-new-combinations-of-cancer-drugs-nci 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/veeva-experts-predict-data-driven-transformation-in-life-sciences-r-d-for-2023 2023-01-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-garners-more-positive-data-in-early-and-late-relapsed 2023-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bioengineered-probiotic-bacteria-could-replace-injections-for-rheumatoid-arthritis-treatment 2023-01-04T18:55:45+00:00 weekly 0.7 https://trial.medpath.com/news/first-made-in-singapore-antibody-drug-conjugate-adc-approved 2023-01-04T03:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/european-health-data-space-to-transform-pharmaceutical-research-access-by-2025 2023-01-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bdr-pharmaceutical-launches-first-generic-apalutamide-in-india-for-prostate-cancer-treatment 2023-01-03T13:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-clinical-trial-designs-for-glioblastoma-a-new-horizon 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-molecular-effects-of-oral-ccr4-antagonist 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-inebilizumab-in-igg4-related-disease-pubmed 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clover-biopharmaceuticals-advances-rsv-vaccine-scb-1019-with-u-s-ind-clearance-for-revaccination-study 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-for-hemophilia-a-new-horizon-in-treatment 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-good-use-of-time-providing-evidence-for-how-effort-is-invested-in 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emergency-use-authorization-eua-revoked-for 2022-12-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-in-patients-with-early-alzheimer-s-disease 2022-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-and-click-therapeutics-expand-digital-therapeutics-alliance-for-schizophrenia-in-460m-deal 2022-12-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eagle-pharmaceuticals-receives-fda-approval-for-additional-indication-for-pemfexy-r-in-combination-with-pembrolizumab-and-platinum-chemotherapy 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nadofaragene-firadenovec-for-high-risk-non-muscle-invasive-bladder-cancer 2022-12-16T20:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-announces-acceptance-of-four-clinical-data-abstracts-at-the-2023-asco-gastrointestinal-cancers-symposium 2022-12-15T12:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopenem 2022-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-innovation-commission-charts-path-for-uk-healthcare-transformation-and-life-sciences-growth 2022-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/challenges-and-advances-in-alzheimer-s-and-parkinson-s-disease-research 2022-12-13T16:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/rsv-emerges-as-hidden-threat-to-elderly-population-causing-8000-annual-deaths-in-uk 2022-12-13T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-advances-digital-health-innovation-in-neurology-through-four-pillar-strategy 2022-12-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elranatamab-achieves-61-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2022-12-10T23:00:37+00:00 weekly 0.7 https://trial.medpath.com/news/agios-presents-updated-pyrukynd-r-mitapivat-data-highlighting-long 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-assisted-therapy-mediates-psycho-social 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intrabio-completes-over-enrollment-for-pivotal-niemann-pick-disease-type-c-trial-data-expected-q2-2023 2022-12-08T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-in-hemoglobin-levels-in-complement-inhibitor-naive-patients-with-pnh 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-despite-significant-safety-challenges-in-clinical-trials 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-life-sciences-council-lacks-transparency-despite-critical-industry-role 2022-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/yonalink-secures-6m-investment-to-transform-clinical-trial-data-management-with-real-time-streaming-technology 2022-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-reports-positive-topline-results-of-its-phase-1-clinical 2022-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-hiv-vaccine-shows-97-antibody-response-rate-in-phase-1-trial 2022-12-01T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-analytics-transform-clinical-trial-design-and-enrollment-strategy 2022-12-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-olutasidenib-for-acute-myeloid-leukemia-subtype 2022-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/industry-leaders-push-for-patient-centric-clinical-trials-through-technology-and-community-engagement 2022-11-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-lecanemab-hailed-as-momentous 2022-11-30T01:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-drug-appears-to-slow-progression-of-alzheimers-disease-in-clinical-trial-but-raises-safety-concerns-cnn 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-reaches-beyond-cancer-penn-today 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-withdraws-tecentriq-from-bladder-cancer-market-following-failed-confirmatory-trial 2022-11-29T16:26:54+00:00 weekly 0.7 https://trial.medpath.com/news/automation-emerges-as-key-solution-to-pharmaceutical-supply-chain-vulnerabilities 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-development-pipeline-shows-promise-for-als-treatment-with-53-candidates-under-investigation 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-and-nhs-england-fast-track-novel-prostate-cancer-treatment-darolutamide-combination-therapy 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rare-disease-drug-development-faces-critical-forecasting-challenges-with-only-5-having-approved-treatments 2022-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/margetuximab-does-not-surpass-trastuzumab-in-terms-of 2022-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-teplizumab-first-disease-modifying-drug-for-type-1-diabetes-prevention 2022-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fierce-biotech-fda-wants-confirmatory-trials-to-be-underway-before 2022-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/raesedo-inc-awarded-3-4m-sttr-grant-to-develop-new-asthma-therapies 2022-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/characteristics-of-measurable-residual-disease-assessment-in-myeloma-a 2022-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-investment-landscape-shows-signs-of-stabilization-after-2021-surge-industry-leaders-report-at-lsx-showcase 2022-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-gantenerumab-fails-to-meet-primary-endpoints-in-phase-3-alzheimer-s-trials 2022-11-14T08:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted 2022-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-starts-pivotal-clinical-trial-with-first-ever-restorative 2022-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paxlovid-may-reduce-risk-of-long-covid-study-suggests 2022-11-09T21:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/aquatic-vaccines-current-status-and-future-development-prospects-in-global-aquaculture 2022-11-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-regeneron-s-libtayo-combination-for-non-small-cell-lung-cancer-treatment 2022-11-09T12:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-first-line-treatment-patterns-and-outcomes-for-brafv600e-mutant-metastatic-colorectal-cancer-in-europe 2022-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-mrd-status-and-number-of-remissions-on-hsct-outcomes-aml-hub 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/baxdrostat-shows-dramatic-blood-pressure-reduction-in-treatment-resistant-hypertension-trial 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-biotech-stocks-for-q2-2023 2022-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/treasure-data-releases-whitepaper-on-maximizing-data-utilization-in-pharmaceutical-industry 2022-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-sues-pfizer-and-biontech-over-mrna-covid-19-vaccine-patent-infringement 2022-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sirona-completes-enrollment-a-leap-in-the-dcb-treatment-of 2022-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-strategies-show-promise-for-rebuilding-brain-tissue-in-neurodegenerative-diseases 2022-11-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/small-business-americus-times-recorder-americus-times-recorder 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/topical-tranexamic-acid-reduces-blood-loss-in-knee-arthroplasty-study-finds 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-invests-92-5m-in-purdue-university-to-advance-pharmaceutical-manufacturing-and-research 2022-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prospective-open-label-single-arm-single-center-follow-up-study-of 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epilepsy 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/monoclonal-antibody-prevents-malaria-infection-in-african-adults 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medical-device-advances-in-the-treatment-of-glioblastoma 2022-10-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genmab-and-abbvie-submit-regulatory-applications-for-epcoritamab-bispecific-antibody-in-relapsed-refractory-b-cell-lymphomas 2022-10-28T12:46:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-astrazeneca-s-dual-immunotherapy-combination-for-unresectable-liver-cancer 2022-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-positive-top-line-results-from 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ivermectin-a-drug-once-touted-as-a-covid-treatment-by-conservatives-doesn-t-improve-recovery-much-clinical-trial-finds 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2g-s-olorofim-shows-44-response-rate-in-phase-2b-trial-for-invasive-fungal-infections 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evotec-receives-2-5m-gates-foundation-grant-for-ipsc-based-teratogenicity-platform 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2022-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value 2022-10-18T11:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/nanopharmaceutics-completes-enrollment-in-phase-2-neuroendocrine-tumor-study-combining-triapine-with-lutetium-lu-177-dotatate 2022-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-acquires-akouos-for-610m-to-expand-gene-therapy-portfolio-in-hearing-loss-treatment 2022-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/attralus-enrolls-first-subject-in-phase-1-clinical-trial-for-at-02-a-pan-amyloid-removal-therapeutic 2022-10-17T11:06:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rmat-and-fast-track-designations-to-caribou-s-allogeneic-car-t-therapy-cb-010-for-b-cell-lymphoma 2022-10-14T18:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-shows-promise-in-melanoma-treatment-two-studies-demonstrate-improved-outcomes-with-pre-surgery-approach 2022-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/significant-improvement-in-overall-survival-with-adjuvant-olaparib-in-high-risk-early-breast-cancer-patients-with-brca1-2-mutations 2022-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insulin-glargine-and-liraglutide-show-superior-performance-in-large-type-2-diabetes-comparative-trial 2022-10-07T16:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/reproxalap-for-dry-eye-disease-aldeyra-therapeutics-inc 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-presents-promising-first-in-human-data-on-restorative 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uab-research-finds-obesity-drug-can-reduce-the-risk-of-type-2-diabetes 2022-10-06T16:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/aerorx-and-hcmed-partner-to-develop-first-nebulized-laba-lama-combination-for-copd-treatment 2022-10-02T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/initial-safety-run-in-results-of-the-phase-3-lotis-5-trial-for-r-r-dlbcl-treatment 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mpn-545-surpass-et-ropeginterferon-alfa-2b-p1101-vs-anagrelide-as 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-significant-weight-loss-benefits-in-overweight-and-obese-patients 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-prospective-single-centre-open-label-single-arm-pilot-study-to 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-watchdog-report-reveals-one-third-of-accelerated-approval-drugs-lack-confirmatory-trial-data 2022-09-30T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-slowing-drug-labelled-historic 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-and-karl-storz-launch-advanced-blue-light-cystoscopy-system-in-us-market 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/population-pharmacokinetic-pharmacodynamic-analyses 2022-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-pivots-to-cns-disorders-with-oral-neuroactive-steroid-pipeline 2022-09-26T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytokine-profile-at-diagnosis-affecting-trough 2022-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genetically-modified-herpes-virus-shows-promise-against-advanced-cancers-in-early-trial 2022-09-22T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-shows-axicabtagene-ciloleucel-outperforms-tisagenlecleucel-in-relapsed-refractory-dlbcl 2022-09-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-reform-in-experimental-treatment-access-balancing-patient-rights-with-sustainable-development 2022-09-17T04:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-affinity-enhanced-t-cell-therapy-in-synovial-sarcoma 2022-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adeno-associated-virus-gene-therapy-for-hemophilia-a-new-therapeutic-paradigm 2022-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/synergia-medical-secures-eur9-million-in-series-b-funding-for-epilepsy-treatment-innovation 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-mersana-therapeutics-xmt-1660-for-triple-negative-breast-cancer-treatment 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-interleukin-2-shows-promise-in-slowing-motor-neurone-disease-progression-in-landmark-mirocals-trial 2022-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tecvayli-shows-promising-outcomes-in-treating-advanced-multiple-myeloma 2022-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/entrepreneurial-accelerator-program-eap-portfolio-company-receives-400000-research-grant-from-the-national-cancer-institute-to-study-a-repurposed-drug-in-treatment-of-glioblastoma 2022-09-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ashvattha-therapeutics-advances-in-medical-research-and-clinical-trials 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-for-trodelvy-in-hr-her2-metastatic-breast-cancer-following-positive-survival-data 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/continuous-circadian-intracerebroventricular 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-receives-approval-for-phase-ii-trial-in-head-and-neck-cancer 2022-09-06T11:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunochemotherapy-shows-promise-for-early-stage-small-cell-lung-cancer-surgery 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-platform-trials-for-coronavirus-covid-19-treatments-gov-uk 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/standardizing-eligibility-criteria-a-new-approach-to 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brodalumab-improves-health-related-quality-of-life-in-psoriasis-patients-itching-remains-a-challenge 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-with-novel-mechanism-of-action-approved-by 2022-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-clinical-trials-enter-new-era-key-protocol-design-and-safety-considerations-emerge 2022-08-28T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-teclistamab-and-talquetamab-on-soluble-bcma-levels-in-multiple-myeloma-treatment 2022-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-submits-application-in-china-for-additional-indication 2022-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/k36-therapeutics-receives-fda-clearance-for-first-in-class-multiple-myeloma-drug-ktx-1001 2022-08-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-rna-technologies-promise-longer-lasting-therapeutics-beyond-mrna 2022-08-22T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase 2022-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cambridge-researchers-successfully-convert-kidney-blood-types-to-universal-o-potentially-expanding-transplant-access 2022-08-15T07:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-decitabine-and-cedazuridine-tablets-for-myelodysplastic-syndromes 2022-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/positive-results-from-b-clear-phase-iib-trial-for-bepirovirsen-in-chronic-hepatitis-b-treatment 2022-08-11T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/as-billionaires-race-to-fund-anti-aging-projects-a-much-discussed-trial-goes-overlooked 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-lyme-disease-vaccine-is-in-its-final-clinical-trial-npr 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tagrisso-plus-savolitinib-shows-promising-49-response-rate-in-egfr-mutated-lung-cancer-with-met-resistance 2022-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nek7-emerges-as-promising-inflammasome-target-despite-novartis-study-raising-questions-about-universal-requirement 2022-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bellaseno-initiates-clinical-trials-for-resorbable-breast-and-chest-implants 2022-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-anlotinib-in-extensive-stage-small-cell-lung-cancer 2022-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-accelerated-approval-program-shows-strong-performance-despite-recent-criticisms-analysis-reveals 2022-07-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxypep-using-antibiotics-to-prevent-stis 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oral-carbapenems-promise-peril-and-pushbacks 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/our-dna-could-affect-the-potency-of-psychedelics-in-the-brain 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/with-merck-known-as-msd-outside 2022-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/senate-finance-committee-revises-medicare-drug-negotiation-policy-removing-automatic-inclusion-of-insulins 2022-07-25T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/sling-therapeutics-initiates-enrollment-in-phase-2b-lids-clinical-trial-for-thyroid-eye-disease 2022-07-25T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/test-reliability-and-compliance-to-a-twelve-month-visual 2022-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-update-on-tigris-clinical-trial-biospace 2022-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cardiofocus-advances-in-pulsed-field-ablation-technology-for-atrial-fibrillation-treatment 2022-07-19T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-approves-two-life-extending-breast-cancer-drugs-after-initial-rejection 2022-07-14T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-novavax-s-protein-based-covid-19-vaccine-for-us-adults 2022-07-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-and-fast-track-designations-to-cv-01-for-recurrent-glioblastoma-treatment 2022-07-13T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-study-of-retifanlimab-incmga00012-in-patients 2022-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-unconditional-ide-approval-from-u-s-fda-to 2022-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-shows-promising-37-5-response-rate-in-phase-i-trial-for-egfr-exon-20-insertion-nsclc 2022-07-06T13:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-fda-accepts-bla-and-grants-priority-review-for-lecanemab-for 2022-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-belumosudil-for-chronic-graft-versus-host-disease-treatment 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/margetuximab-versus-trastuzumab-in-patients-with 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-groundbreaking-stem-cell-therapy-trial-for-drug-resistant-epilepsy-shows-dramatic-seizure-reduction 2022-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-nvs-gets-positive-chmp-opinion-for-scemblix-in-cml 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-plus-steroids-shows-superior-early-response-in-first-line-acute-gvhd-treatment 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-antibody-drug-conjugate-l-dos47-shows-safety-profile-in-phase-i-ii-nsclc-trial 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-therapy-demonstrates-superior-efficacy-over-bispecific-antibodies-in-relapsed-refractory-follicular-lymphoma 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-vaers-analysis-confirms-safety-profile-of-pneumococcal-vaccines-across-multiple-formulations 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hong-kong-study-reveals-comparable-safety-profiles-between-coronavac-and-bnt162b2-covid-19-vaccines 2022-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-receives-positive-chmp-opinion-for-scemblix-r-a-novel 2022-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-approval-for-novartis-tafinlar-mekinist-broadens-braf-mek-cancer-combo-use 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/penn-researchers-earn-nearly-1-billion-from-mrna-covid-vaccine-technology-royalties 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-outcomes-with-fedratinib-in-myelofibrosis-patients-post-ruxolitinib-discontinuation 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-on-brentuximab-vedotin-combination-therapy-for-relapsed-refractory-dlbcl-shows-promising-results 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-gets-accelerated-fda-approval-for-dabrafenib-trametinib 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-clinical-development-of-oncolytic-viruses 2022-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/valbiotis-announces-major-success-in-phase-ii-heart-clinical-study-for-totum-070 2022-06-13T16:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/sling-therapeutics-launches-with-35m-series-a-financing-to-develop-oral-small-molecule-for-thyroid-eye-disease 2022-06-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lead-pharma-and-oxeltis-secure-eur800k-grant-to-develop-first-in-class-dlbcl-therapy 2022-06-09T10:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-bluerock-therapeutics-expands-to-europe-with-new-berlin-site 2022-06-09T01:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsy-technology-fda-s-latest-guidance-supports-cooley 2022-06-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dbv-technologies-announces-positive-topline-results-from-phase-3-epitope-trial-of-viaskin-peanut-in-peanut-allergic-toddlers 2022-06-07T20:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/dostarlimab-achieves-100-complete-response-rate-in-rectal-cancer-trial-with-mismatch-repair-deficiency 2022-06-06T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-tirzepatide-shows-unprecedented-22-5-weight-loss-in-phase-3-obesity-trial 2022-06-06T10:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-fifth-neulasta-biosimilar 2022-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eagle-pharmaceuticals-submits-nda-for-landiolol-ultra-short-acting-beta-blocker-for-critical-care-tachycardia 2022-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/risankizumab-as-induction-therapy-for-crohn-s-disease-results 2022-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-risankizumab-and-upadacitinib-show-promise-in-phase-3-ibd-trials-published-in-the-lancet 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-latest-phase-2-clinical-data-of-its-differentiated-cd73 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-shows-atacicept-s-potential-in-treating-iga-nephropathy 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ivosidenib-plus-azacitidine-for-certain-patients-with-acute-myeloid-leukemia 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-evaluation-of-laxaplus-barij-r-and-polyethylene-glycol-in-pediatric-functional-constipation 2022-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-fda-approves-epsolay-cream-for-rosacea-treatment-spa-clinic 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-elian-granules-in-treating-chronic-atrophic-gastritis 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-of-axicabtagene-ciloleucel-for-the-treatment-of 2022-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teclistamab-daratumumab-combination-shows-promising-results-in-heavily-pretreated-multiple-myeloma-patients 2022-05-20T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-faces-patent-infringement-lawsuit-over-lipid-nanoparticle-technology-in-covid-19-vaccine 2022-05-19T09:35:35+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-nct04857372-uchicago-medicine 2022-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sorrento-s-license-partner-lee-s-pharm-announces-full-enrollment-in-phase-iii-trial-of-socazolimab-for-es-sclc 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-acquires-global-rights-to-aav-gene-therapy 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-pathological-complete-response-after-nivolumab-plus 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cullinan-oncology-and-taiho-pharmaceutical-forge-275m-strategic-collaboration-for-egfr-inhibitor-cln-081-tas6417 2022-05-12T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/single-cell-study-reveals-jun-as-key-regulator-in-cardiovascular-aging 2022-05-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/delaware-jury-awards-bgi-333-8-million-in-dna-sequencing-patent-victory-against-illumina 2022-05-06T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-advances-from-manufacturing-innovations-to-solid-tumor-breakthroughs 2022-05-05T17:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/pharmather-secures-u-s-patent-for-advanced-ketamine-production-technology 2022-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-resminostat-and-resmain-study-update-4sc-ag 2022-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-receives-fda-breakthrough-device-designation-for-novel-therapy 2022-05-03T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-trastuzumab-deruxtecan-for-her2-low-metastatic-breast-cancer 2022-05-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/six-monthly-injection-shows-promise-as-alternative-to-daily-blood-pressure-medication-in-global-trial 2022-04-27T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/dual-targeting-car-t-therapies-show-promise-in-overcoming-b-cell-cancer-treatment-resistance 2022-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-promising-results-for-bioresorbable-polymer-scaffold-in-spinal-cord-injury-patients 2022-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/current-clinical-trials-in-traumatic-brain-injury 2022-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diet-and-gut-microbiota-shape-development-of-regulatory-t-cells-study-finds 2022-04-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/canada-abandons-controversial-drug-pricing-reforms-following-court-ruling 2022-04-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-therapies-transform-multiple-myeloma-treatment-landscape-car-t-bispecifics-lead-innovation-wave 2022-04-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-sotorasib-for-kras-g12c-mutated-metastatic-nsclc 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-extends-review-of-biologics-license-application 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-defines-positive-mental-health-literacy-as-key-to-psychological-wellbeing 2022-04-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bo-112-plus-pembrolizumab-shows-promise-in-pd-1-resistant-advanced-melanoma 2022-04-12T20:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/aeglea-biotherapeutics-submits-bla-for-pegzilarginase-as-first-potential-treatment-for-arginase-1-deficiency 2022-04-12T10:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-tagawa-on-the-investigation-of-225ac-j591-and-177lu 2022-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-drug-treatment-effective-for-crohn-s-disease-strictures 2022-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-to-seek-first-ever-fda-approval-in-rett-syndrome 2022-04-07T10:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/direct-biologics-reveals-successful-outcomes-from-exit-covid-19-phase-ii-clinical-trial 2022-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-2b-trial-of-rt234-a-novel-inhaled-therapy-for-pulmonary-arterial-hypertension 2022-04-05T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-completes-alfapump-implantations-in-poseidon-study 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pacritinib-paves-a-unique-lane-of-treatment-for-select 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-clears-cansinobio-covid-19-vaccine-for-clinical-trials-national-globalnews-ca 2022-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-fda-approval-of-investigational-new-drug-application-for-anti-cd112r-monoclonal-antibody-for-treatment-of-advanced-solid-tumors-financial-post 2022-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharmaceuticals-launches-cobra-trial-testing-novel-cu-64-sar-bispsma-imaging-agent-for-biochemically-recurrent-prostate-cancer 2022-04-01T16:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-dose-expansion-trial-of-brentuximab-vedotin-and-lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2022-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aion-labs-launches-ai-initiative-to-revolutionize-antibody-drug-development 2022-03-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hhs-terminates-500-million-in-federal-mrna-vaccine-research-funding-under-kennedy-leadership 2022-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/us-food-and-drug-administration-revises-emergency-use 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-watch-13-approvals-and-five-topline-phase-iii-readouts 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-companies-see-massive-potential-in-connected-health-despite-low-adoption-rates 2022-03-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vr-and-ar-technologies-transform-pharmaceutical-manufacturing-training-promising-50-faster-onboarding 2022-03-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/orphan-drug-market-set-to-reach-350-billion-by-2028-as-rare-disease-treatments-expand 2022-03-18T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-and-acceptability-of-a-mobile-application-to-monitor-opioid-use-post-cesarean-section 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-immune-checkpoint-inhibitor-based-systemic-therapy-for-hepatocellular-carcinoma 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eskayef-pharmaceuticals-becomes-third-bangladeshi-company-to-receive-us-fda-approval-for-manufacturing-facility 2022-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-begins-phase-2-and-3-trial-of-covid-19-antiviral-paxlovid-in-children-ages-6-to-17-cnn 2022-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promising-brain-cancer-vaccine-survaxm-enters-phase-2b-trial-for-newly-diagnosed-glioblastoma 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-carvykti-car-t-cell-therapy-for-multiple 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-efficacy-of-treatment-regimens-for-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma 2022-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-receives-fda-orphan-drug-designation-for-its-novel-claudin-18-2-x 2022-03-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-role-of-immunotherapy-after-progression-in-renal-cell-carcinoma 2022-03-02T14:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-medicine-gains-mainstream-acceptance-as-mental-health-crisis-drives-research-innovation 2022-03-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-missing-in-regulatory-documents-for-extended-release-methylphenidate-applications 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-shows-promise-for-advanced-hepatocellular-carcinoma 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/primary-care-sites-emerge-as-vital-hub-for-clinical-research-innovation-experts-highlight 2022-02-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-wholly-ai-developed-drug-enters-phase-1-trials 2022-02-25T04:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/new-sanofi-and-gsk-vaccine-demonstrates-strong-protection-against-severe-covid-19-in-clinical-trials-cnn 2022-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-shows-immune-checkpoint-inhibitors-benefit-nsclc-patients-with-poor-performance-status 2022-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/agios-announces-fda-approval-of-pyrukynd-r-mitapivat-as-globenewswire 2022-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-highlights-positive-effects-of-medical-cannabis-on-ptsd 2022-02-16T15:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2022-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/challenges-and-recommendations-in-glioblastoma-clinical-trials 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-rise-therapeutics 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-plan-to-fast-track-pfizer-vaccine-for-kids-under-5-fails-to-deliver-leaving-parents-waiting-until-april 2022-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chromadex-strengthens-patent-portfolio-with-two-new-continuation-patents-for-nicotinamide-riboside-manufacturing 2022-02-09T11:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-for-pancreatic-cancer-anti-pd-l-1-based-strategy 2022-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-fda-acceptance-of-new-drug-globenewswire 2022-02-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-covid-19-vaccine-spikevax-receives-full-fda-approval-marking-company-s-first-licensed-product 2022-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/calliditas-reports-positive-phase-iii-results-for-nefecon-plans-full-fda-approval-filing-in-2023 2022-01-28T07:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-research-suggests-cancer-drug-could-help-flush-hiv-from-its-hiding-spots 2022-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/transitioning-ongoing-studies-to-the-eu-clinical-trial-regulation 2022-01-25T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/can-cbd-treat-covid-19-clinical-trials-still-needed-researchers-warn-national-globalnews-ca 2022-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-receives-ce-mark-approval-for-advanced-dual-energy-thermocool-smarttouch-sf-catheter 2022-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adimab-announces-2021-clinical-pipeline-update-with-12-new-partner-programs 2022-01-19T05:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-tranexamic-acid-in-hematologic-malignancy-patients-a-randomized-clinical-trial 2022-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/edap-announces-positive-pre-clinical-results-for-hifu-ablation-in-pancreatic-cancer-treatment 2022-01-13T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-prediction-model-for-alzheimer-s-disease-progression-and-donepezil-treatment-effects 2022-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-announces-corporate-and-portfolio-updates-at-j-p-morgan-healthcare-conference 2022-01-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maze-therapeutics-announces-190-million-financing 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-a-s-updates-on-vision-3x3-strategy-and-2022-milestones 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-medical-ceo-highlights-2021-achievements-and-2022-objectives 2022-01-05T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-astrazeneca-s-lynparza-for-prostate-cancer-despite-scottish-approval 2022-01-04T16:00:00+00:00 weekly 0.7